Proteomics International Laboratories has launched the PromarkerD diabetic kidney disease (DKD) predictive test in Australia.
The test is said to predict the DKD development risk in individuals with type 2 diabetes up to four years before the appearance of clinical symptoms.
Go deeper with GlobalData
Its availability in the country represents a key step in the company’s strategy to commercialise the product worldwide.
It is stated to assist Australian doctors in the early detection of at-risk individuals, allowing them to intervene on time to either slow or prevent the progression of the disease.
The company noted that PromarkerD will be accessible via healthcare professional referrals in Western Australia and the Northern Territory, with plans to extend its availability nationwide.
Proteomics is actively engaging with diabetes clinics, professional organisations, and primary care networks across the nation to facilitate the adoption of the test.
The company is also exploring reimbursement options with health insurers, patient advocacy groups, and government entities to ensure the test is affordable for all diabetic Australians.
The test’s introduction to the market will begin with a direct-to-consumer approach, setting the stage for potential out-licensing agreements with diagnostics industry players.
Proteomics’ expansion plans include the US and European markets. It has recently opened a Clinical Laboratory Improvement Amendment (CLIA) certified Reference Laboratory in California, US, and is in discussions with potential partners in Europe.
Proteomics International Laboratories managing director Dr Richard Lipscombe said: “We are excited to officially launch PromarkerD in Australia, particularly on World Kidney Day, which underscores the importance of early diagnosis and prevention.
“Diabetic kidney disease is a major public health challenge, and PromarkerD offers a highly innovative, accurate, and accessible way to identify those most at risk. By enabling proactive management, we aim to reduce the personal and financial costs associated with this life-threatening condition.”
In June 2024, the company announced a collaboration with medical device sales agency Growth Medics to widen the reach of PromarkerD within the EU.
